Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong

被引:83
作者
Chan, Raphael C. Y. [1 ]
Hui, Mamie
Chan, Edward W. C.
Au, T. K.
Chin, Miu. L.
Yip, Chun K.
AuYeang, Carrie K. W.
Yeung, Christina Y. L.
Kam, Kai M.
Yip, Peter C. W.
Cheng, Augustine E. B.
机构
[1] Chinese Univ Hong Kong, Dept Microbiol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China
[2] Ctr Hlth Protect, TB Reference Lab, Publ Hlth Lab Ctr, Dept Hlth, Kowloon, Hong Kong, Peoples R China
关键词
MPAC; MDR-TB; tuberculosis;
D O I
10.1093/jac/dkm054
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To characterize 250 drug-resistant Mycobacterium tuberculosis (MTB) isolates in Hong Kong with respect to their drug susceptibility phenotypes to five common anti-tuberculosis drugs (ofloxacin, rifampicin, ethambutol, isoniazid and pyrazinamide) and the relationship between such phenotypes and the patterns of genetic mutations in the corresponding resistance genes (gyrA, rpoB, embB, katG, inhA, ahpC and pncA). Methods: The MIC values of the aforementioned anti-tuberculosis drugs were determined for each of the 250 drug-resistant MTB clinical isolates by the absolute concentration method. Genetic mutations in the corresponding resistance genes in these MTB isolates were identified by PCR-single-stranded conformation polymorphism/multiplex PCR amplimer conformation analysis (SSCP/MPAC), followed by DNA sequencing of the purified PCR products. Results: Resistance to four or five drugs was commonly observed in these MTB isolates; such phenotypes accounted for over 34% of the 250 isolates. The most frequently observed phenotypes were those involving both rifampicin and isoniazid, with or without additional resistance to the other drugs. A total of 102 novel mutations, which accounted for 80% of all mutation types detected in the 7 resistance genes, were recovered. Correlation between phenotypic and mutational data showed that genetic changes in the gyrA, rpoB and katG genes were more consistently associated with a significant resistance phenotype. Despite this, however, a considerable proportion of resistant MTB isolates were found to harbour no detectable mutations in the corresponding gene loci. Conclusions: These findings expand the spectrum of potential resistance-related mutations in MTB clinical isolates and help consolidate the framework for the development of molecular methods for delineating the drug susceptibility profiles of MTB isolates in clinical laboratories.
引用
收藏
页码:866 / 873
页数:8
相关论文
共 33 条
  • [1] The occurrence of rare rpoB mutations in rifampicin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait
    Ahmad, S
    Mokaddas, E
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 (03) : 205 - 212
  • [2] Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis:: Functional analysis of mutant enzymes
    Aubry, A
    Veziris, N
    Cambau, E
    Truffot-Pernot, C
    Jarlier, V
    Fisher, LM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) : 104 - 112
  • [3] Fitness of antibiotic-resistant microorganisms and compensatory mutations
    Böttger, EC
    Springer, B
    Pletschette, M
    Sander, P
    [J]. NATURE MEDICINE, 1998, 4 (12) : 1343 - 1344
  • [4] CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21
  • [5] Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil
    Cardoso, RF
    Cooksey, RC
    Morlock, GP
    Barco, P
    Cecon, L
    Forestiero, F
    Leite, CQF
    Sato, DN
    Shikama, MD
    Mamizuka, EM
    Hirata, RDC
    Hirata, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) : 3373 - 3381
  • [6] Current medical treatment for tuberculosis
    Chan, ED
    Iseman, MD
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2002, 325 (7375): : 1282 - 1286
  • [7] Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates
    Cheng, AFB
    Yew, WW
    Chan, EWC
    Chin, ML
    Hui, MMM
    Chan, RCY
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) : 596 - 601
  • [8] COHN AG, 1997, GEOINFORMATICA, V1, P1
  • [9] Crofton J., 1997, GUIDELINES MANAGEMEN
  • [10] Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?
    Di Perri, G
    Bonora, S
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (03) : 593 - 602